ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2018
A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neural Computation-Based Methods for the Early Diagnosis and Prognosis of Alzheimer's Disease Not Using Neuroimaging Biomarkers: A Systematic Review.Journal of Alzheimer's disease : JAD · 2024Pooled it
- Gut-brain health effects of PREbiotics in older adults with suspected COgnitive DEcline: design of the PRECODE randomised placebo-controlled trial.Frontiers in nutrition · 2026Article
- Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge.Journal of medical Internet research · 2025Article
- Pick a PACC: Comparing domain-specific and general cognitive composites in Alzheimer disease research.Neuropsychology · 2024Article
- Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Assessment of Neurocognitive Functions, Olfaction, Taste, Mental, and Psychosocial Health in COVID-19 in Adults: Recommendations for Harmonization of Research and Implications for Clinical Practice.Journal of the International Neuropsychological Society : JINS · 2022Review
- Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2022Review
- Multimodal immersive trail making-virtual reality paradigm to study cognitive-motor interactions.Journal of neuroengineering and rehabilitation · 2021Article
- Alterations in resting-state network dynamics along the Alzheimer's disease continuum.Scientific reports · 2020Article
- Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.NeuroImage. Clinical · 2020Article
- The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.Alzheimer's research & therapy · 2019Article
- Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.Alzheimer's research & therapy · 2018Article
- Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test-retest reliability and feasibility of use.
methodsWe performed a test-retest study with 2-3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples
resultsForty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. DISCUSSION: The CFC is a stable and feasible measure in MCI and mild AD dementia, and thereby meets important quality metrics for clinically meaningful outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.